Pulmatrix Inc.
16
0
0
12
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
25.0%
4 terminated/withdrawn out of 16 trials
75.0%
-11.5% vs industry average
0%
0 trials in Phase 3/4
8%
1 of 12 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA
Role: lead
Allergic Bronchopulmonary Aspergillosis Prescreening Study
Role: collaborator
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of PUR3100 in Health Adults
Role: lead
A Phase 1b Study of PUR1800 in Patients With COPD
Role: lead
Study in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis
Role: lead
A Phase I/II Double-Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of RUT058-60
Role: lead
Safety, Tolerability and Pharmacokinetics of PUR1900 (Itraconazole Powder) in Healthy Volunteers and Adults With Asthma
Role: lead
Safety and Efficacy Study of Inhaled PUR003 on a Controlled Influenza Virus Challenge in Healthy Adult Subjects
Role: lead
A PK Study to Evaluate PUR0200 and a Reference Product in Healthy Subjects
Role: lead
21 Day Cumulative Skin Irritation of RUT058-60
Role: lead
A Safety, Pharmacokinetic and Pharmacodynamic Study of PUR0200 in COPD Patients
Role: lead
A Safety and Tolerability Study OF PUR118 In Subjects With Cystic Fibrosis
Role: lead
Evaluation of the Effect of PUR118 on Ozone Induced Airway Inflammation in Healthy Normal Volunteers
Role: lead
Safety, Tolerability, and Pharmacodynamic Effect Study of PUR118
Role: lead
Effect of PUR003 on Asthma
Role: lead
Determination of the in Vitro Effects of Cationic Airway Lining Modulators (CALM) on Chronic Obstructive Pulmonary Disease (COPD) Sputum
Role: lead
All 16 trials loaded